Findings seen in people with type 2 diabetes<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Nov. 1, 2024 (HealthDay News) — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study presented at the annual meeting of the American College of Gastroenterology, held from Oct. 25 to 30 in Philadelphia.<\/p>\n
Temitope Olasehinde, M.D., from Case Western Reserve University in Cleveland, and colleagues examined the impact of GLP-1 RA use on EO-CRC risk. The analysis included data from roughly 1.8 million patients (aged younger than 50 years) with a diagnosis of type 2 diabetes (subsequently prescribed antidiabetic medications) but with no prior CRC diagnosis identified from the TriNetX health research network.<\/p>\n
The researchers found that among 77,688 propensity-matched patients, the GLP-1 RA cohort was significantly more likely to be older (44.21 versus 36.45 years), female (56.3 versus 50.9 percent), White (54.3 versus 53.4 percent), and non-Hispanic\/Latino (65.1 versus 57.1 percent) and have more comorbidities and higher body mass index (36.78 versus 30.62 kg\/m2<\/sup>) compared with the no GLP-1 RA cohort. The GLP-1 RA cohort had significantly lower odds of developing EO-CRC (0.4 versus 0.7 percent) versus the no GLP-1 RA cohort. Those with obesity taking GLP-1 RAs had significantly lower odds of developing EO-CRC versus patients with obesity not taking GLP-1 RAs.<\/p>\n “Future randomized controlled studies are needed to validate these findings, which may have significant implications for CRC prevention in younger patients,” the authors write.<\/p>\n